656 related articles for article (PubMed ID: 16014412)
21. Status of treatment strategies for Hutchinson-Gilford progeria syndrome with a focus on prelamin: A posttranslational modification.
Chen X; Yao H; Andrés V; Bergo MO; Kashif M
Basic Clin Pharmacol Toxicol; 2022 Oct; 131(4):217-223. PubMed ID: 35790078
[TBL] [Abstract][Full Text] [Related]
22. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells.
Cao K; Graziotto JJ; Blair CD; Mazzulli JR; Erdos MR; Krainc D; Collins FS
Sci Transl Med; 2011 Jun; 3(89):89ra58. PubMed ID: 21715679
[TBL] [Abstract][Full Text] [Related]
23. Presence and distribution of progerin in HGPS cells is ameliorated by drugs that impact on the mevalonate and mTOR pathways.
Clements CS; Bikkul MU; Ofosu W; Eskiw C; Tree D; Makarov E; Kill IR; Bridger JM
Biogerontology; 2019 Jun; 20(3):337-358. PubMed ID: 31041622
[TBL] [Abstract][Full Text] [Related]
24. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis.
Young SG; Fong LG; Michaelis S
J Lipid Res; 2005 Dec; 46(12):2531-58. PubMed ID: 16207929
[TBL] [Abstract][Full Text] [Related]
25. Progerin impairs chromosome maintenance by depleting CENP-F from metaphase kinetochores in Hutchinson-Gilford progeria fibroblasts.
Eisch V; Lu X; Gabriel D; Djabali K
Oncotarget; 2016 Apr; 7(17):24700-18. PubMed ID: 27015553
[TBL] [Abstract][Full Text] [Related]
26. Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts.
Gabriel D; Roedl D; Gordon LB; Djabali K
Aging Cell; 2015 Feb; 14(1):78-91. PubMed ID: 25510262
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic involvement in Hutchinson-Gilford progeria syndrome: a mini-review.
Arancio W; Pizzolanti G; Genovese SI; Pitrone M; Giordano C
Gerontology; 2014; 60(3):197-203. PubMed ID: 24603298
[TBL] [Abstract][Full Text] [Related]
28. Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated.
Yang SH; Andres DA; Spielmann HP; Young SG; Fong LG
J Clin Invest; 2008 Oct; 118(10):3291-300. PubMed ID: 18769635
[TBL] [Abstract][Full Text] [Related]
29. All-trans retinoic acid and rapamycin normalize Hutchinson Gilford progeria fibroblast phenotype.
Pellegrini C; Columbaro M; Capanni C; D'Apice MR; Cavallo C; Murdocca M; Lattanzi G; Squarzoni S
Oncotarget; 2015 Oct; 6(30):29914-28. PubMed ID: 26359359
[TBL] [Abstract][Full Text] [Related]
30. Dermal fibroblasts in Hutchinson-Gilford progeria syndrome with the lamin A G608G mutation have dysmorphic nuclei and are hypersensitive to heat stress.
Paradisi M; McClintock D; Boguslavsky RL; Pedicelli C; Worman HJ; Djabali K
BMC Cell Biol; 2005 Jun; 6():27. PubMed ID: 15982412
[TBL] [Abstract][Full Text] [Related]
31. Accumulation of distinct prelamin A variants in human diploid fibroblasts differentially affects cell homeostasis.
Candelario J; Borrego S; Reddy S; Comai L
Exp Cell Res; 2011 Feb; 317(3):319-29. PubMed ID: 20974128
[TBL] [Abstract][Full Text] [Related]
32. Nuclear localization signal deletion mutants of lamin A and progerin reveal insights into lamin A processing and emerin targeting.
Wu D; Flannery AR; Cai H; Ko E; Cao K
Nucleus; 2014; 5(1):66-74. PubMed ID: 24637396
[TBL] [Abstract][Full Text] [Related]
33. Disruption of lamin B1 and lamin B2 processing and localization by farnesyltransferase inhibitors.
Adam SA; Butin-Israeli V; Cleland MM; Shimi T; Goldman RD
Nucleus; 2013; 4(2):142-50. PubMed ID: 23475125
[TBL] [Abstract][Full Text] [Related]
34. DNA damage responses in progeroid syndromes arise from defective maturation of prelamin A.
Liu Y; Rusinol A; Sinensky M; Wang Y; Zou Y
J Cell Sci; 2006 Nov; 119(Pt 22):4644-9. PubMed ID: 17062639
[TBL] [Abstract][Full Text] [Related]
35. Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice.
Fong LG; Ng JK; Meta M; Coté N; Yang SH; Stewart CL; Sullivan T; Burghardt A; Majumdar S; Reue K; Bergo MO; Young SG
Proc Natl Acad Sci U S A; 2004 Dec; 101(52):18111-6. PubMed ID: 15608054
[TBL] [Abstract][Full Text] [Related]
36. Hutchinson-Gilford progeria syndrome through the lens of transcription.
Prokocimer M; Barkan R; Gruenbaum Y
Aging Cell; 2013 Aug; 12(4):533-43. PubMed ID: 23496208
[TBL] [Abstract][Full Text] [Related]
37. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation.
Yang SH; Meta M; Qiao X; Frost D; Bauch J; Coffinier C; Majumdar S; Bergo MO; Young SG; Fong LG
J Clin Invest; 2006 Aug; 116(8):2115-21. PubMed ID: 16862216
[TBL] [Abstract][Full Text] [Related]
38. Farnesyltransferase inhibitor treatment restores chromosome territory positions and active chromosome dynamics in Hutchinson-Gilford progeria syndrome cells.
Mehta IS; Eskiw CH; Arican HD; Kill IR; Bridger JM
Genome Biol; 2011 Aug; 12(8):R74. PubMed ID: 21838864
[TBL] [Abstract][Full Text] [Related]
39. Prelamin A and lamin A appear to be dispensable in the nuclear lamina.
Fong LG; Ng JK; Lammerding J; Vickers TA; Meta M; Coté N; Gavino B; Qiao X; Chang SY; Young SR; Yang SH; Stewart CL; Lee RT; Bennett CF; Bergo MO; Young SG
J Clin Invest; 2006 Mar; 116(3):743-52. PubMed ID: 16511604
[TBL] [Abstract][Full Text] [Related]
40. Rescue of heterochromatin organization in Hutchinson-Gilford progeria by drug treatment.
Columbaro M; Capanni C; Mattioli E; Novelli G; Parnaik VK; Squarzoni S; Maraldi NM; Lattanzi G
Cell Mol Life Sci; 2005 Nov; 62(22):2669-78. PubMed ID: 16261260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
